Filing Flows

Filing Flows › Stoke Therapeutics (STOK) › Next earnings date

Stoke Therapeutics (STOK) earnings: missed the estimate

Stoke Therapeutics (STOK) reported on Oct 29, 2026 and missed the EPS estimate: −$1.08 against −$0.91 (-18.1%). Revenue was $11.3M for Q3 2026, +6% year over year. It beat the EPS estimate in 20% of the quarters on record.

Last result−18.1% vs estimate
Beat rate20%

The last report

Stoke Therapeutics reported revenue of $11.3M for the third quarter 2026 (+6% Y/Y), net loss $73.6M. How it makes money → · Every quarter →

Stoke Therapeutics: EPS against the estimate, last 5 reportsStoke Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.57−$0.65Nov 25−$0.74−$0.97Mar 26−$0.82−$0.79May 26−$0.78−$0.93Aug 26−$0.91−$1.08Oct 26
Latest (Oct 26): Estimate −$0.91, Reported −$1.08.

Stoke Therapeutics' latest quarter

Stoke Therapeutics, Q3 2026: revenue $11.3M (+6% year over year), operating margin -686.9%, net loss $73.6M, operating cash flow −$62.7M. The chart follows the revenue to costs, profit and cash.

Questions

Did Stoke Therapeutics beat earnings?

Stoke Therapeutics (STOK) reported on Oct 29, 2026 and missed the EPS estimate: −$1.08 against −$0.91 (-18.1%).

When does STOK report earnings?

The next date is not set yet.

Does Stoke Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 20% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.